Analyst Andrew Fein of H.C. Wainwright maintained a Buy rating on Dyne Therapeutics (DYN – Research Report), retaining the price target of $46.00.
Andrew Fein has given his Buy rating due to a combination of factors that highlight Dyne Therapeutics’ promising advancements with DYNE-251. The recent data from the Phase 1/2 Deliver trial indicates sustained clinical improvement and stabilization in key endpoints, such as SV95C, which are supported by the EMA. The drug’s ability to achieve higher dystrophin expression levels compared to existing ASO-based treatments, without new safety concerns, positions it favorably in the current therapeutic landscape.
Furthermore, DYNE-251’s once-a-month dosing regimen offers a significant advantage over the current standard of care, which requires more frequent dosing and has issues with patient adherence. The potential for full-length dystrophin expression also makes it an attractive option compared to gene therapies that limit future treatment opportunities. With the registrational cohort fully enrolled and the possibility of submitting a BLA for accelerated approval in the US by late 2025, Dyne Therapeutics is well-positioned to compete in the evolving market of muscle-penetrating modalities.
In another report released today, Piper Sandler also reiterated a Buy rating on the stock with a $48.00 price target.